The European Commission has also approved Celgene's new blood cancer drug pomalidomide for use in combination dexamethasone for adult patients with relapsed and refractory multiple myeloma who ...

Bristol-Myers Squibb acquires 2seventy bio for $286M, marking the end of a once-promising biotech. Check out if this is a ...

NHS patients in England with newly-diagnosed multiple myeloma can be treated with Celgene’s Revlimid as maintenance therapy after a stem cell transplant, after new guidance from NICE.

The results of this report were complemented by another similar initiative, the meta-analysis Evaluate Minimal Residual Disease as an Intermediate Clinical Endpoint for Multiple Myeloma (EVIDENCE ...

During a Case-Based Roundtable® event, Robert Z. Orlowski, MD, PhD, discussed the case of a patient who had progression of ...

Multiple myeloma (MM), which is caused by the transformation ... diagnosed with MM in combination with melphalan (Alkeran; Celgene) and prednisone. This combination, also known as VMP, produced ...

NEW YORK – Bristol Myers Squibb and 2seventy Bio on Monday entered into a merger agreement in which BMS will acquire 2seventy for $286 million, ending the firms' cost-sharing agreement for the ...

Sales of Celgene's blockbuster Revlimid, which treats the blood cancer multiple myeloma, rose nearly 18 percent to $2.45 billion, but slightly below analysts' estimates of $2.47 billion.